Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Animal scale-up.

× No keyword cloud information.

35 in total

1. The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid.

Authors: B B BRODIE; H KURZ; L S SCHANKER
Journal: J Pharmacol Exp Ther Date: 1960-09 Impact factor: 4.030

2. The fate of thiopental in man and a method for its estimation in biological material.

Authors: B B BRODIE; L C MARK
Journal: J Pharmacol Exp Ther Date: 1950-01 Impact factor: 4.030

3. Studies of the enzymatic deamination of cytosine arabinoside. II. Properties of the deaminase of human liver.

Authors: G W Camiener
Journal: Biochem Pharmacol Date: 1967-09-09 Impact factor: 5.858

4. Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity.

Authors: G W Camiener; C G Smith
Journal: Biochem Pharmacol Date: 1965-10 Impact factor: 5.858

5. Thiopental pharmacokinetics.

Authors: K B Bischoff; R L Dedrick
Journal: J Pharm Sci Date: 1968-08 Impact factor: 3.534

6. Relationships among area under serum concentration curve, dose, and half-life for novobiocin administered in combination with tetracycline.

Authors: J G Wagner; R E Damiano
Journal: J Clin Pharmacol J New Drugs Date: 1968 Mar-Apr

7. A useful thin-layer chromatography method for the determination of cytidine aminohydrolase activity in serum.

Authors: L T Mulligan; L B Mellett
Journal: J Chromatogr Date: 1969-09-09

Review 8. Comparative drug metabolism.

Authors: L B Mellett
Journal: Prog Drug Res Date: 1969

9. Some pharmacological consequences of species variation in rates of metabolism.

Authors: B B Brodie; W D Reid
Journal: Fed Proc Date: 1967 Jul-Aug

10. Studies of the enzymatic deamination of cytosine arabinoside. 3. Substrate requirements and inhibitors of the deaminase of human liver.

Authors: G W Camiener
Journal: Biochem Pharmacol Date: 1967-09-09 Impact factor: 5.858

71 in total

1. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver.

Authors: S Kanamitsu; K Ito; Y Sugiyama
Journal: Pharm Res Date: 2000-03 Impact factor: 4.200

2. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors: Dhaval K Shah; Alison M Betts
Journal: J Pharmacokinet Pharmacodyn Date: 2011-12-06 Impact factor: 2.745

3. Significance of binding to Na,K-ATPase in the tissue distribution of ouabain in guinea pigs.

Authors: H Harashima; M Mamiya; M Yamazaki; Y Sugiyama; Y Sawada; T Iga; M Hanano
Journal: Pharm Res Date: 1992-04 Impact factor: 4.200

4. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance.

Authors: Ardith W El-Kareh; Timothy W Secomb
Journal: Neoplasia Date: 2004 Mar-Apr Impact factor: 5.715

5. Pharmacokinetic modeling of the dogfish shark (Squalus acanthias): distribution and urinary and biliary excretion of phenol red and its glucuronide.

Authors: P M Bungay; R L Dedrick; A M Guarino
Journal: J Pharmacokinet Biopharm Date: 1976-10

6. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.

Authors: Sihem Ait-Oudhia; Jean-Michel Scherrmann; Wojciech Krzyzanski
Journal: J Pharmacol Exp Ther Date: 2010-05-25 Impact factor: 4.030

Animal scale-up.